Secukinumab improves scalp pain, itching, scaling and quality of life in patients with moderate-to-severe scalp psoriasis

References

• Van der Vleuten JM, van de Kerkhof PC. Management of scalp psoriasis: guidelines for corticosteroid use in combination treatment. Drugs. 2001;61:1593–8.
   PubMed Web of Science ®Google Scholar
• National Psoriasis Foundation. Scalp psoriasis. 2016. Available from: https://www.psoriasis.org/about-psoriasis/specific-locations/scalp
   Google Scholar
• Meffert J. Psoriasis Medscape. 2016. Available from: http://emedicine.medscape.com/article/1943419-overview
   Google Scholar
• Renton C. Diagnosis and treatment of adults with scalp psoriasis. Nurs Stand. 2014;28:35–9.
   PubMedGoogle Scholar
• Wozel G. Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areas. Clin Dermatol. 2008;26:448–59.
   PubMed Web of Science ®Google Scholar
• American Academy of Dermatology. Scalp psoriasis. 2016. Available from: https://www.aad.org/public/diseases/hair-and-scalp-problems/scalp-psoriasis#symptoms
   Google Scholar
• Kragballe K, Menter A, Lebwohl M, International Psoriasis Council, et al. Long-term management of scalp psoriasis: perspectives from the International Psoriasis Council. J Dermatolog Treat. 2013;24:188–92.
   PubMed Web of Science ®Google Scholar
• Chen AC, Yeung J, Chren MM. Scalpdex: a quality-of-life instrument for scalp dermatitis. Arch Dermatol. 2002;138:803–7.
   PubMed Web of Science ®Google Scholar
• Mroweitz U, Macheleidt O, Eicke C. Effective treatment and improvement of quality of life in patients with scalp psoriasis by topical use of calcipotriol/betamthesaone (Xamiol-gel): results from a study in 721 patients. J Dtsch Dermatol Ges. 2011;9:825–31.
   PubMed Web of Science ®Google Scholar
• Tyring S, Bagel J, Lynde C, et al. Patient-reported outcomes in moderate-to-severe plaque psoriasis with scalp involvement: results from a randomized, double-blind, placebo-controlled study of etanercept. J Eur Acad Dermatol Venereol. 2013;27:125–8.
   PubMed Web of Science ®Google Scholar
• Zampieron A, Buja A, Fusco M, et al. Quality of life in patients with scalp psoriasis. G Ital Dermatol Venereol. 2015;150:309–16.
   PubMed Web of Science ®Google Scholar
• Papp K, Berth-Jones J, Kragballe K, et al. Scalp psoriasis: a review of current topical treatment options. J Eur Acad Dermatol Venereol. 2007;21:1151–60.
   PubMed Web of Science ®Google Scholar
• Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010;2:52ra72.
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2013;168:412–21.
   PubMed Web of Science ®Google Scholar
• Rich P, Sigurgeirsson B, Thaci D, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. 2013;168:402–11.
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, ERASURE Study Group; FIXTURE Study Group, et al. Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med. 2014;371:326–38.
   PubMed Web of Science ®Google Scholar
• Bagel J, Lynde C, Tyring S, et al. Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept. J Am Acad Dermatol. 2012;67:86–92.
   PubMed Web of Science ®Google Scholar
• Thaçi D, Daiber W, Boehncke WH, et al. Calcipotriol solution for the treatment of scalp psoriasis: evaluation of efficacy, safety and acceptance in 3,396 patients. Dermatology (Basel). 2001;203:153–6.
   PubMed Web of Science ®Google Scholar
• Langley RG, Feldman SR, Nyirady J, et al. The 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat. 2015;26:23–31.
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70:871–81.
   PubMed Web of Science ®Google Scholar
• Nguyen CM, Leon A, Danesh M, et al. Improvement of nail and scalp psoriasis using apremilast in patients with chronic psoriasis: phase 2b and 3, 52-week randomized, placebo-controlled trial results. J Drugs Dermatol. 2016;15:272–6.
   PubMedGoogle Scholar
• Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826–50.
   PubMed Web of Science ®Google Scholar
• American Academy of Dermatology Work Group, Menter A, Korman NJ, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65:137–74.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Psoriasis: assessment and management. NICE guidelines [CG153]. 2012. Available from: http://www.nice.org.uk/guidance/cg153
   Google Scholar
• Thaci D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73:400–9.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Reich K, Tsai TF, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study. J Am Acad Dermatol. 2017;76:60–9.
   PubMed Web of Science ®Google Scholar